הכנסות ממכירות החברה bioaffinitytech.com (BIAF)

bioAffinity Technologies (BIAF) develops non-invasive tests for lung cancer detection via sputum analysis. The company's sales metrics on GURU.Markets demonstrate daily demand dynamics, where the 0.01 level reflects current revenue. Patents and AI-driven cell analysis algorithms protect the business from competition. The increasing adoption of CyPath Lung in laboratories provides a stable operational effect currently.

For bioAffinity Technologies (BIAF), revenue dynamics reflect the speed of commercializing diagnostic tests amid high market resistance and slow product adoption into clinical practice. Analyzing the company's sales performance, an investor sees a daily cash inflow; however, short-term sales spikes should not be extrapolated over an annual period to avoid overestimating business growth rates.